
- /
- Supported exchanges
- / DU
- / RHO5.DU
ROCHE HLDG DR - Dusseldorf Stock Exchang (RHO5 DU) stock market data APIs
ROCHE HLDG DR - Dusseldorf Stock Exchang Financial Data Overview
There is no Profile data available for RHO5.DU.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ROCHE HLDG DR - Dusseldorf Stock Exchang data using free add-ons & libraries
Get ROCHE HLDG DR - Dusseldorf Stock Exchang Fundamental Data
ROCHE HLDG DR - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-01-30
- EPS/Forecast: NaN
Get ROCHE HLDG DR - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ROCHE HLDG DR - Dusseldorf Stock Exchang News

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
– Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries – – Evrysdi tablet can be stored at room temperature and offers the same demonstrated ef...


FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
F. Hoffmann-La Roche Ltd Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same d...

New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
– Nearly half of patients on Gazyva plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treat...

New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
F. Hoffmann-La Roche Ltd Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvem...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.